These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 20458068)
1. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Lashley D; Palace J; Jayawant S; Robb S; Beeson D Neurology; 2010 May; 74(19):1517-23. PubMed ID: 20458068 [TBL] [Abstract][Full Text] [Related]
2. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. Lorenzoni PJ; Scola RH; Kay CS; Filla L; Miranda AP; Pinheiro JM; Chaouch A; Lochmüller H; Werneck LC J Neurol Sci; 2013 Aug; 331(1-2):155-7. PubMed ID: 23790237 [TBL] [Abstract][Full Text] [Related]
3. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Burke G; Hiscock A; Klein A; Niks EH; Main M; Manzur AY; Ng J; de Vile C; Muntoni F; Beeson D; Robb S Neuromuscul Disord; 2013 Feb; 23(2):170-5. PubMed ID: 23219351 [TBL] [Abstract][Full Text] [Related]
4. Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Rodríguez Cruz PM; Palace J; Ramjattan H; Jayawant S; Robb SA; Beeson D Neurology; 2015 Sep; 85(12):1043-7. PubMed ID: 26296515 [TBL] [Abstract][Full Text] [Related]
5. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children. Tsao CY Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645 [TBL] [Abstract][Full Text] [Related]
6. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Schara U; Barisic N; Deschauer M; Lindberg C; Straub V; Strigl-Pill N; Wendt M; Abicht A; Müller JS; Lochmüller H Neuromuscul Disord; 2009 Dec; 19(12):828-32. PubMed ID: 19837590 [TBL] [Abstract][Full Text] [Related]
7. DOK7 congenital myasthenic syndrome. Palace J Ann N Y Acad Sci; 2012 Dec; 1275():49-53. PubMed ID: 23278577 [TBL] [Abstract][Full Text] [Related]
8. Clinical features of the DOK7 neuromuscular junction synaptopathy. Palace J; Lashley D; Newsom-Davis J; Cossins J; Maxwell S; Kennett R; Jayawant S; Yamanashi Y; Beeson D Brain; 2007 Jun; 130(Pt 6):1507-15. PubMed ID: 17452375 [TBL] [Abstract][Full Text] [Related]
9. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Müller JS; Herczegfalvi A; Vilchez JJ; Colomer J; Bachinski LL; Mihaylova V; Santos M; Schara U; Deschauer M; Shevell M; Poulin C; Dias A; Soudo A; Hietala M; Aärimaa T; Krahe R; Karcagi V; Huebner A; Beeson D; Abicht A; Lochmüller H Brain; 2007 Jun; 130(Pt 6):1497-506. PubMed ID: 17439981 [TBL] [Abstract][Full Text] [Related]
10. DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine. Santos M; Cruz S; Peres J; Santos L; Tavares P; Basto JP; Salgado V; Valverde AH Neuromuscul Disord; 2018 Mar; 28(3):278-282. PubMed ID: 29395672 [TBL] [Abstract][Full Text] [Related]
12. Dok-7/MuSK signaling and a congenital myasthenic syndrome. Yamanashi Y; Higuch O; Beeson D Acta Myol; 2008 Jul; 27(1):25-9. PubMed ID: 19108574 [TBL] [Abstract][Full Text] [Related]
13. Intra-familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Yeung WL; Lam CW; Ng PC Dev Med Child Neurol; 2010 Oct; 52(10):e243-4. PubMed ID: 20370815 [No Abstract] [Full Text] [Related]
14. [Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy--The French National Congenital Myasthenic Syndrome Network experience]. Eymard B; Stojkovic T; Sternberg D; Richard P; Nicole S; Fournier E; Béhin A; Laforêt P; Servais L; Romero N; Fardeau M; Hantaï D; Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S45-55. PubMed ID: 23452772 [TBL] [Abstract][Full Text] [Related]